Forecasting the Global Transmucosal Drug Delivery Devices Market in 2024: Size, Growth Rate, and Segment Breakdown

The transmucosal drug delivery devices global market report 2024 from The Business Research Company provides comprehensive market statistics, including global market size, regional shares, competitor market share, detailed segments, trends, and opportunities. This report offers an in-depth analysis of current and future industry scenarios, delivering a complete perspective for thriving in the industrial automation software market.

Transmucosal Drug Delivery Devices Market, 2024 report by The Business Research Company offers comprehensive insights into the current state of the market and highlights future growth opportunities.

Market Size -
The transmucosal drug delivery devices market size has grown strongly in recent years. It will grow from $46.16 billion in 2023 to $50.24 billion in 2024 at a compound annual growth rate (CAGR) of 8.8%.  The  growth in the historic period can be attributed to the need for rapid relief from angina, the effectiveness of sublingual delivery for quick absorption into the bloodstream, desire to bypass gastrointestinal degradation, development of buccal tablets, the need for non-invasive delivery of peptides and proteins.

The transmucosal drug delivery devices market size is expected to see strong growth in the next few years. It will grow to $71.69 billion in 2028 at a compound annual growth rate (CAGR) of 9.3%.  The growth in the forecast period can be attributed to the development of smart drug delivery systems, increased prevalence of chronic diseases, growing focus on personalized medicine, aging population with higher medication needs, and increased awareness. Major trends in the forecast period include expansion in therapeutic applications, customizing drug delivery devices for personalized medicine, regulatory approvals and guidelines, emerging markets, eco-friendly devices, and innovative formulations.

Order your report now for swift delivery @
https://www.thebusinessresearchcompany.com/report/transmucosal-drug-delivery-devices-global-market-report

Scope Of Transmucosal Drug Delivery Devices Market
The Business Research Company's reports encompass a wide range of information, including:

1. Market Size (Historic and Forecast): Analysis of the market's historical performance and projections for future growth.

2. Drivers: Examination of the key factors propelling market growth.

3. Trends: Identification of emerging trends and patterns shaping the market landscape.

4. Key Segments: Breakdown of the market into its primary segments and their respective performance.

5. Focus Regions and Geographies: Insight into the most critical regions and geographical areas influencing the market.

6. Macro Economic Factors: Assessment of broader economic elements impacting the market.

Transmucosal Drug Delivery Devices Market Overview

Market Drivers -
The growing prevalence of chronic diseases is expected to propel the growth of the transmucosal drug delivery devices market going forward. A chronic disease refers to a long-lasting condition that typically progresses slowly and persists over time, often requiring ongoing medical management to control symptoms and prevent complications. Chronic diseases are rising as a result of, lifestyle factors, aging populations, environmental factors, healthcare system challenges, and urbanization. Transmucosal drug delivery devices are used in chronic diseases to provide controlled and efficient delivery of medications, ensuring sustained therapeutic levels for managing symptoms and improving patient adherence. For instance, in July 2021, according report published by the International Diabetes Federation (IDF), a Belgium-based national diabetes association, about 537 million people worldwide have diabetes. The number of cases has been increasing over the past few decades, and the IDF predicts 783 million people will have diabetes by 2045 an increase of 46%. Therefore, the increasing prevalence of chronic diseases is driving the growth of the transmucosal drug delivery devices market.

Market Trends -
Major companies operating in transmucosal drug delivery devices are developing innovative smart platform, such as proprietary transdermal patch delivery platforms that enhance drug absorption and improve patient compliance and convenience. Proprietary transdermal patch delivery platforms refer to specialized technologies owned by companies for administering medications through the skin, ensuring controlled release, and enhanced therapeutic outcomes. For instance, in January 2024, Starton Therapeutics Inc, a US-based biotechnology company, launched STARSILON, a novel proprietary transdermal patch delivery platform, for a longer duration to achieve therapeutic delivery of difficult-to-formulate APIs. It expands transdermal drug delivery options for challenging active pharmaceutical ingredients (APIs), enhancing therapeutic efficacy with sustained delivery rates.

The transmucosal drug delivery devices market covered in this report is segmented –

1) By Type: Passive Transdermal Drug Delivery, Active Transdermal Drug Delivery
2) By Drug Type: Buccal Tablets, Oral Sprays, Sublingual Films And Wafers, Gels, Medicated Confectionery, Other Drug Types
3) By Indication: Pain Management, Addiction Treatment, Hormonal Therapies, Others Indications
4) By End User: Academic And Research Institutes, Pharmaceutical And Biotechnology Companies, Diagnostic Laboratories, Hospitals

Get an inside scoop of the transmucosal drug delivery devices market, Request now for Sample Report @
https://www.thebusinessresearchcompany.com/sample.aspx?id=16812&type=smp

Regional Insights -
North America was the largest region in the transmucosal drug delivery devices market in 2023. The regions covered in the transmucosal drug delivery devices market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Key Companies -
Major companies operating in the transmucosal drug delivery devices market are  Johnson & Johnson, Bayer AG, Sanofi SA, Bristol-Myers Squibb Company, Abbott Laboratories, Novartis AG, Becton Dickinson and Company, Viatris Inc., Teva Pharmaceutical Industries Ltd., Catalent Inc., AptarGroup, Glenmark Pharmaceuticals Limited, Stevanato Group S.p.A, Lifevision Healthcare Private Limited, Noven Pharmaceuticals, SAVA Healthcare Limited, Antares Pharma Inc., Kaizen Pharmaceuticals Pvt. Ltd., Lucky Pharma Pvt. Ltd., Maya Biotech Pvt. Ltd, AdvaCare Pharma LLP, Satsuma Pharmaceuticals Inc., Biophar Lifesciences Private Limited, Fibovil Pharmaceuticals Private Limited, Slan Medicinal Holdings Ltd.

Table of Contents
1. Executive Summary
2. Transmucosal Drug Delivery Devices Market Report Structure
3. Transmucosal Drug Delivery Devices Market Trends And Strategies
4. Transmucosal Drug Delivery Devices Market – Macro Economic Scenario
5. Transmucosal Drug Delivery Devices Market Size And Growth
…..
27. Transmucosal Drug Delivery Devices Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model